DexCom earnings beat by $0.03, revenue topped estimates
Sebastian Burzacchi, the Chief Operating Officer of Management Services Organization at Alignment Healthcare, Inc. (NASDAQ:ALHC), has recently sold a portion of his holdings in the company. The stock has seen remarkable performance, gaining over 250% in the past year and currently trades near its 52-week high of $17.27. According to InvestingPro analysis, the stock appears fairly valued, with analysts setting price targets between $9 and $21. According to an SEC filing, Burzacchi sold a total of 6,694 shares of common stock on March 19, 2025. The transactions were executed at prices ranging from $15.73 to $17.12 per share, resulting in a total value of approximately $109,788.
These sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following these transactions, Burzacchi’s direct ownership in Alignment Healthcare stands at 250,378 shares.
In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16 compared to the forecast of -0.18. The company’s revenue exceeded projections, reaching $701.2 million against the expected $674.97 million. This performance marks the company’s first year of adjusted EBITDA profitability and highlights its robust growth, with a 59% increase in membership. Additionally, Alignment Healthcare provided guidance for 2025, projecting revenue between $3.72 billion and $3.78 billion and forecasting Health Plan Membership to grow to between 227,000 and 233,000 members by the end of the year.
Analyst firms have shown optimism regarding Alignment Healthcare’s future. Piper Sandler raised its price target for the company to $21, maintaining an Overweight rating, citing the company’s scalable strategies and high Star Ratings as key drivers for success. Raymond (NSE:RYMD) James also lifted its price target to $19, reiterating a Strong Buy rating after the company’s strong fourth-quarter performance. The firm noted Alignment Healthcare’s ability to grow at a rate of 20% or more annually while enhancing EBITDA profitability. These recent developments reflect investor confidence in Alignment Healthcare’s growth trajectory and its ability to deliver better-than-expected financial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.